|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | BCLC策略:预后预测和治疗推荐2022版更新显示文摘2018版BCLC预后和治疗推荐策略发布后,肝细胞癌(简称HCC)的研究又取得了重大进展。本次更新基于肝癌各领域的研究进展结果。重点关注影响策略的重要研究进展。虽然近年的研究结果成绩斐然,但将其引入为临床医生和研究者提供行动依据的循证模型指南来说证据效力依然不够确切。本文对该问题进行分析,阐述了为HCC患者制定个体化治疗临床决策所需的批判性思维和专业知识。 | Reig M Forner A Rimola J Ferrer-Fabrega J Burrel M Garcia-Criado A Kelley RK Galle PR Mazzaferro V Salem R Sangro B Singal AG Vogel A Fuster J Ayuso C Bruix J 刘永凡(摘译) 崔笑(摘译) 耿小平(审校) | 2022 | 肝胆外科杂志2022，30，5： | 80 |
| 2 | Helicobacter species sequences in liver samples from patients with and without hepatocellular carcinoma显示文摘AIM:Only a minority of patients carrying a defined viral aetiologic agent develop cirrhosis and ultimately hepatocellular carcinoma (HCC), the mechanism underlying the worsening is still undefined. Experimental infection by Helicobacter hepaticusin mice causes chronic hepatitis and HCC and recently, more Helicobacter species (Helicobacter spp.) have been detected in the liver of patients suffering from cholestatic diseases and HCC arising from non-cirrhotic liver. We investigated whether Helicobacter spp. sequences could be detected in the liver of patients with cirrhosis and HCC compared to subjects with metastasis to liver from colon cancer.METHODS:Twenty-three liver samples from patients operated upon for HCC superimposed on hepatitis C virus (HCV)-related cirrhosis and 6 from patients with resected metastases from colorectal cancer, were tested by polymerase chain reaction for presence of genomic 16S rRNA of Helicobacter genus using specific primers. DNA sequencing and cagA gene analysis were also performed.RESULTS:Genomic sequences of Helicobacter spp. were found in 17 of 20 (85%) liver samples from patients with HCC and in 2 of 6 samples from patients with liver metastasis.In three samples of the first group the result was uncertain.Hpyloriwas revealed in 16 out of 17 positive samples and Helicobacter pullorum in the other.CONCLUSION: Helicobacter spp., carcinogenic in mice,were found at a higher frequency in the liver of patients with HCV-related cirrhosis and HCC than those in patients without primary liver disease. | RinaldoPellicano MarioRizzetto AntonioPonzetto Vincenzo Mazzaferro Walter Franco Grigioni MiguelAngelCutufia SharmilaFagoonee LorenzoSilengo | 2004 | World Journal of Gastroenterology2004，10，4： | 28 |
| 3 | Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions显示文摘 | Luigi Bolondi Andrew Burroughs Jean-Fran?ois Dufour Peter Galle Vincenzo Mazzaferro Fabio Piscaglia Jean Raoul Bruno Sangro | 2012 | Semin Liver Dis2012，，04： | 7 |
| 4 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial显示文摘 | Jordi Bruix Jean-Luc Raoul Morris Sherman Vincenzo Mazzaferro Luigi Bolondi Antonio Craxi Peter R. Galle Armando Santoro Michel Beaugrand Angelo Sangiovanni Camillo Porta Guido Gerken Jorge A. Marrero Andrea Nadel Michael Shan Marius Moscovici Dimitris Vo | 2012 | Journal of Hepatology2012，，4： | 6 |
| 5 | Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis显示文摘 | Vincenzo Mazzaferro Josep M Llovet Rosalba Miceli Sherrie Bhoori Marcello Schiavo Luigi Mariani Tiziana Camerini Sasan Roayaie Myron E Schwartz Gian Luca Grazi René Adam Peter Neuhaus Mauro Salizzoni Jordi Bruix Alejandro Forner Luciano De Carlis Umberto | 2009 | Lancet Oncology2009，，1： | 4 |
| 6 | Vascular calcification,bone and mineral metabolism after kidney transplantation显示文摘The development of end stage renal failure can be seen as a catastrophic health event and patients with this condition are considered at the highest risk of cardiovascular disease among any other patient groups and risk categories. Although kidney transplantation was hailed as an optimal solution to such devastating disease, many issues related to immune-suppressive drugs soon emerged and it became evident that cardiovascular disease would remain a vexing problem. Progression of chronic kidney disease is accompanied by profound alterations of mineral and bone metabolism that are believed to have an impact on the cardiovascular health of patients with advanced degrees of renal failure. Cardiovascular risk factors remain highly prevalent after kidney transplantation, some immune-suppression drugs worsen the risk profile of graft recipients and the alterations of mineral and bone metabolism seen in end stage renal failure are not completely resolved. Whether this complex situation promotes progression of vascular calcification, a hall-mark of advanced chronic kidney disease, and whether vascular calcifications contribute to the poor cardiovascular outcome of post-transplant patients is reviewed in this article. | Luis D’Marco Antonio Bellasi Sandro Mazzaferro Paolo Raggi | 2015 | World Journal of Transplantation2015，5，4： | 4 |
| 7 | Transarterial chemoembolization using 40 μm drug eluting beads for hepatocellular carcinoma显示文摘AIM To assess the safety and efficacy of transarterial chemoembolization(TACE) of hepatocellular carcinoma(HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment.METHODS Drug eluting bead TACE(DEB-TACE) using a new generation of microspheres(embozene tandem,40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensatedcirrhosis.Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors(RECIST) and modified RECIST(m RECIST) guidelines applied to computed tomography or magnetic resonance imaging.Eleven out of the 48 treated patients treated progressed on to receive liver orthotopic transplantation(OLT).This allowed for histological analysis on the treated explanted nodules.RESULTS DEB-TACE with 40 μm showed a good safety profile without major complications or 30-d mortality.The objective response rate of treated tumors was 72.6% and 26.7% according to m RECIST and RECIST respectively.Histological examination in 11 patients assigned to OLT showed a necrosis degree > 90% in 78.6% of cases.The overall time to progression was 13 mo(11-21).CONCLUSION DEB-TACE with 40 μm particles is an effective treatment for the treatment of HCC in early-intermediate patients(Barcelona Clinic Liver Cancer stage A/B) with a good safety profile and good results in term of objective response rate and necrosis. | Giorgio Greco Tommaso Cascella Antonio Facciorusso Roberto Nani Rodolfo Lanocita Carlo Morosi Marta Vaiani Giuseppina Calareso Francesca G Greco Antonio Ragnanese Marco A Bongini Alfonso V Marchianò Vincenzo Mazzaferro Carlo Spreafico | 2017 | World Journal of Radiology2017，9，5： | 3 |
| 8 | Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study<.-- Doctopic: TAS -->显示文摘 | Carlo Sposito Luigi Mariani Alessandro Germini Maria Flores Reyes Marco Bongini Glenda Grossi Sherrie Bhoori Vincenzo Mazzaferro | 2013 | Journal of Hepatology2013，，1： | 3 |
| 9 | Resection and Liver Transplantation for Hepatocellular Carcinoma显示文摘 | Josep Llovet Myron Schwartz Vincenzo Mazzaferro | 2005 | Semin Liver Dis2005，，02： | 3 |
| 10 | Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation: A Prospective Study显示文摘 | Vincenzo Mazzaferro Carlo Battiston Stefano Perrone Andrea Pulvirenti Enrico Regalia Raffaele Romito Dario Sarli Marcello Schiavo Francesco Garbagnati Alfonso Marchianò Carlo Spreafico Tiziana Camerini Luigi Mariani Rosalba Miceli Salvatore Andreola | 2004 | Annals of Surgery2004，，5： | 3 |
| 11 | A Prospective Policy Development to Increase Split-Liver Transplantation for 2 Adult Recipients: Results of a 12-Year Multicenter Collaborative Study显示文摘 | Paolo Aseni Tullia Maria De Feo Luciano De Carlis Umberto Valente Michele Colledan Umberto Cillo Giorgio Rossi Vincenzo Mazzaferro Matteo Donataccio Nicola De Fazio Enzo Andorno Patrizia Burra | 2014 | Annals of Surgery2014，，1： | 3 |
| 12 | Liver Transplantation for Hepatocellular Carcinoma显示文摘 | Vincenzo Mazzaferro MD Yun Shin Chun MD Ronnie T. P. Poon MS PhD Myron E. Schwartz MD Francis Y. Yao MD J. Wallis Marsh MD Sherrie Bhoori MD Sung-Gyu Lee MD PhD | 2008 | Annals of Surgical Oncology2008，，4： | 2 |
| 13 | Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study显示文摘 | Carlo Sposito Luigi Mariani Alessandro Germini Maria Flores Reyes Marco Bongini Glenda Grossi Sherrie Bhoori Vincenzo Mazzaferro | 2013 | Journal of Hepatology2013，，1： | 2 |
| 14 | Sorafenib in advanced hepatocellular carcinoma显示文摘 | Llovet JM Ricci S Mazzaferro V | | New England Journal of Medicine0，，： | 2 |
| 15 | Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinical–Radiological Outcomes and Safety Profile显示文摘 | Carlo Spreafico Tommaso Cascella Antonio Facciorusso Carlo Sposito Lanocita Rodolfo Carlo Morosi Enrico M. Civelli Marta Vaiani Sherrie Bhoori Alessandro Pellegrinelli Alfonso Marchianò Vincenzo Mazzaferro | 2015 | CardioVascular and Interventional Radiology2015，，1： | 2 |
| 16 | Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib显示文摘 | Anja Lachenmayer Clara Alsinet Radoslav Savic Laia Cabellos Sara Toffanin Yujin Hoshida Augusto Villanueva Beatriz Minguez Philippa Newell Hung-Wen Tsai Jordi Barretina Swan Thung Stephen C. Ward Jordi Bruix Vincenzo Mazzaferro Myron Schwartz Scott L. Fri | 2012 | Clinical Cancer Research2012，，18： | 2 |
| 17 | Yttrium‐90 radioembolization for intermediate‐advanced hepatocellular carcinoma: A phase 2 study显示文摘 | Vincenzo Mazzaferro Carlo Sposito Sherrie Bhoori Raffaele Romito Carlo Chiesa Carlo Morosi Marco Maccauro Alfonso Marchianò Marco Bongini Rodolfo Lanocita Enrico Civelli Emilio Bombardieri Tiziana Camerini Carlo Spreafico | 2013 | Hepatology2013，，： | 2 |
| 18 | Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization显示文摘 | J.-L. Raoul B. Sangro A. Forner V. Mazzaferro F. Piscaglia L. Bolondi R. Lencioni | 2010 | Cancer Treatment Reviews2010，，3： | 2 |
| 19 | Pattern and management of recurrent hepatocellular carcinoma after liver transplantation显示文摘 | Enrico Regalia Luigi Rainero Fassati Umberto Valente Andrea Pulvirenti Isabella Damilano Giovanni Dardano Fabrizio Montalto Jorgelina Coppa Vincenzo Mazzaferro | 1998 | Journal of Hepato-Biliary-Pancreatic Surgery1998，，1： | 2 |
| 20 | Sorafenib in advanced hepatocellular carcinoma显示文摘 | Llovet JM Ricci S Mazzaferro V | 2008 | N Engl J Med2008，359，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员